


COVID-19 IMPACT

This report has been affected by the COVID-19 pandemic. All forecasts and analysis have been revised to reflect the current view including the effect of the pandemic and associated recession.

RESEARCH REPORT



Cell Based Assay & High Content Screening Markets

Forecasts by Application. With Executive and Consultant
Guides and including Customized Forecasting and Analysis.

2021 to 2025



Howe Sound Research is a market research and consulting company based in Vancouver, British Columbia, Canada. In our spare time we like to sail in a large body of water nearby called Howe Sound. We publish market research reports that address scientific industries with an emphasis on Biotechnology and Clinical Diagnostic markets. We consider ourselves experts in these areas.

We approach market research differently than other companies. At any one time we have a limited number of reports and we update them frequently, sometimes several times a year. Our reports are prepared by people who understand the industry and have worked and studied in the area. This contrasts with the many research mills who produce canned reports on the Handbag market one day and the XRay market the next.

Our intellectual property is encryption protected. If you have issues with this or would like to upgrade to a corporate license that is not encrypted, please contact us at the email above.

Please feel free to contact us if you have any questions. We believe in customer service and are more than willing to provide after sales assistance and custom data.

All Rights Reserved. This document contains copyrighted intellectual property. No part of it may be circulated, copied, quoted, or otherwise reproduced without the approval of Howe Sound Research.

Please respect our intellectual property and do not distribute this document beyond the terms of your license.

Table of Contents

i. Market Guides	16
iA. Situation Analysis & COVID-19 Impact	17
iB. Guide for Executives and Marketing Staff	19
iC. Guide for Investment Analysts and Management Consultants	20
1. Introduction and Market Definition	21
1.1 What are Cell Based Assays?	22
1.2 Clinical Trial Failures.....	25
1.2.1 Immuno-oncology Plays a Leading Role in Cell Based Assays	27
1.2.2 Infectious Disease Will Play a Larger Role	28
1.3 Market Definition	29
1.3.1 Market Size.....	29
1.3.2 Currency	29
1.3.3 Years.....	29
1.4 Methodology	31
1.4.1 Authors	31
1.4.2 Sources.....	31
1.5 U.S. Medical Market and Pharmaceutical Research Spending - Perspective.....	33
1.5.1 U.S. Expenditures for Pharmaceutical Research	33

2. Cell Based Assays – Guide to Technology.....	34
2.1 Cell Cultures	35
2.1.1 Cell Lines	35
2.1.2 Primary Cells	43
2.1.3 Stem Cells	44
2.1.3.1 iPSC's – The Special Case	46
2.2 Cell Assays.....	47
2.3 Cell Viability Assays	49
2.3 Cell Proliferation Assays	51
2.4 Cytotoxicity Assays.....	52
2.5 Cell Senescence Assays	52
2.6 Apoptosis.....	53
2.7 Autophagy	54
2.8 Necrosis.....	55
2.9 Oxidative Stress.....	55
2.10 2D vs. 3D	57
2.11 Signalling Pathways, GPCR	59
2.12 Immune Regulation & Inhibition	61
2.13 Reporter Gene Technology	62
2.14 CBA Design & Development	62
2.15 Cell Based Assays – The Takeaway.....	63
3. Industry Overview	65
3.1 Players in a Dynamic Market	66

3.1.1 Academic Research Lab	67
3.1.2 Contract Research Organization	67
3.1.3 Genomic Instrumentation Supplier.....	68
3.1.5 Cell Line and Reagent Supplier	68
3.1.6 Pharmaceutical Company	68
3.1.7 Audit Body	69
3.1.8 Certification Body	69
4. Market Trends	71
4.1 Factors Driving Growth	72
4.1.1 Candidate Growth.....	73
4.1.2 Immuno-oncology	73
4.1.3 Genomic Blizzard	75
4.1.4 Technology Convergence	75
4.1.5 The Insurance Effect	76
4.2 Factors Limiting Growth	78
4.2.1 CBA Development Challenges	78
4.2.2 Instrument Integration	79
4.2.3 Protocols	79
4.3 Technology Development	80
4.3.1 3D Assays	80
4.3.2 Automation	80
4.3.3 Software	81
4.3.4 Primary Cells	81

4.3.5 Signalling and Reporter Genes	82
4.3.6 The Next Five Years	83
5. Cell Based Assays Recent Developments	84
5.1 Recent Developments – Importance and How to Use This Section ..	85
5.1.1 Importance of These Developments	85
5.1.2 How to Use This Section.....	85
Axxam and FUJIFILM Cellular Dynamics Announce Strategic Alliance ..	85
Cancer Genetics to Acquire Organoid Startup Stemonix.....	87
Curi Bio Acquires Artificial Intelligence Firm Dana Solutions	88
CRISPR Screens Uncover Novel Cancer Therapy Targets	89
ERS Genomics Licenses CRISPR-Cas9 Patents to Axxam	94
New Transcriptomics Assay Facilitates Compound Screens	95
Carta Biosciences Betting on Gene Interaction Mapping	99
High-throughput Identifies cancer drug candidates	103
Velabs Therapeutics partners with Alytas Therapeutics to develop a novel immune-based therapy for obesity	104
InSphero platform selected to test Cycleron's sGC stimulator technology	105
OcellO to provide in vitro research services to Merus.....	107
Charles River Laboratories to acquire Citoxlab	108
Reaction Biology Corporation Purchases ProQinase GmbH.....	109
Cisbio extends its assay portfolio for immuno-oncology drug discovery	111
STEMCELL Technologies Launches Next-Generation Culture System ...	112

Abcam Acquires Calico Biolabs 113

Evotec announces achievement in Celgene alliance utilizing iPSC screening 114

Fujifilm Cellular Dynamics Inc. launches iCELL Microglia 115

Cisbio and Excellerate Bioscience partner..... 117

Horizon Discovery extends CRISPR Screening Service to primary human T cells..... 118

6. Profiles of Key Cell Based Assay Companies 120

Abcam..... 121

Agilent..... 123

Aurora Instruments Ltd. 125

Axxam 127

Beckman Coulter Diagnostics 129

Becton, Dickinson and Company..... 130

BioIVT 132

Bio-Rad Laboratories, Inc. 134

BioTek Instruments..... 137

BioVision, Inc. 139

BMG Labtech..... 141

Cell Biolabs, Inc..... 142

Cell Signaling Technology, Inc. 143

Charles River Laboratories..... 145

Cisbio Bioassays 147

Corning, Inc..... 149

Cytovale	151
Enzo Life Sciences, Inc.	152
Eurofins DiscoverX Corporation	154
Evotec AG	156
Excellerate Bioscience	158
Fujifilm Cellular Dynamics International	159
Genedata	161
Hemogenix	162
Horizon Discovery	164
Invivogen	166
Leica Biosystems	168
Lonza Group Ltd.	170
Luminex Corp	172
Merck & Co., Inc.	174
Miltenyi Biotec	176
Molecular Devices	177
Nanon	179
Ncardia	181
New England Biolabs, Inc.	183
Olympus	185
Origene Technologies	187
Perkin Elmer	188
Promega	190

Qiagen Gmbh	192
Reaction Biology	194
Recursion Pharma	195
Roche Diagnostics	197
Sartorius.....	199
Sartorius-ForteBio	201
Sartorius-IntelliCyt	203
Sony Biotechnology	204
SPT Labtech.....	206
Stemcells Technologies Canada Inc.	208
Tecan	210
Thermo Fisher Scientific Inc.	212
Vitro Biopharma.....	214
7. Global Market Size	216
7.1 Global Market Overview by Country	217
7.1.1 Table – Global Market by Country	217
7.1.2 Chart - Global Market by Country	219
7.2 Global Market by User - Overview	220
7.2.1 Table – Global Market by User	220
7.2.2 Chart – Global Market by User – Base/End Year Comparison ...	221
7.2.3 Chart – Global Market by User – Base Year	222
7.2.4 Chart – Global Market by User – End Year.....	223
7.2.5 Chart – Global Market by User – Share by Year.....	224

7.3 Global Market by Product Class - Overview	225
7.3.1 Table – Global Market by Product Class	225
7.3.2 Chart – Global Market by Product Class – Base/End Year Comparison	226
7.3.3 Chart – Global Market by Product Class – Base Year	227
7.3.4 Chart – Global Market by Product Class – End Year	228
7.3.5 Chart – Global Market by Product Class – Share by Year	229
8. Global Market by User Type	230
8.1 Pharma	231
8.1.1 Table Pharma – by Country.....	231
8.1.2 Chart - Pharma Growth	232
8.2 Research.....	233
8.2.1 Table Research – by Country	233
8.2.2 Chart - Research Growth.....	234
8.3 Industry/Cosmetic	235
8.3.1 Table Industry/Cosmetic – by Country	235
8.3.2 Chart - Industry/Cosmetic Growth	236
9. Cell Based Assay by Product Class.....	237
9.1 Instrument	238
9.1.1 Table Instrument – by Country	238
9.1.2 Chart - Instrument Growth.....	239
9.2 Reagent.....	240
9.2.1 Table Reagent – by Country	240

9.2.2 Chart - Reagent Growth.....	241
9.3 Services.....	242
9.3.1 Table Services – by Country	242
9.3.2 Chart - Services Growth.....	243
9.4 Software.....	244
9.4.1 Table Software – by Country	244
9.4.2 Chart - Software Growth	245
10. Appendices	246
10.1 FDA Cancer Drug Approvals by Year	247
10.2 Clinical Trials Started 2010 to 2016.....	248
10.3 Share of Pharma R&D by Country	249

Table of Tables

Table 1 The Large Variety of Cell Lines.....	36
Table 2 Some Common Viability Assays	50
Table 3 Oxidative Stress Related Diseases	56
Table 4 Important Signalling Pathways	59
Table 5 Market Players by Type	66
Table 6 Five Factors Driving Growth	72
Table 7 Three Factors Limiting Growth	78
Table 8 - Global Market by Region.....	217
Table 9 Global Market by User	220
Table 10 Global Market by Product Class	225
Table 11 Pharma by Country.....	231
Table 12 Research by Country	233
Table 13 Industry/Cosmetic by Country.....	235
Table 14 Instrument by Country	238
Table 15 Reagent by Country	240
Table 16 Services by Country	242
Table 17 Software by Country	244

Table of Figures

Figure 1 Reasons for clinical Failure by Phase	25
Figure 2 Immunotherapy Clinical Trial Growth	28
Figure 3 Pharmaceutical Research Expenditures 2001 to 2017 (\$Billion) ...	33
Figure 4 Oxidative Stress and Free Radical Toxicity	56
Figure 5 FDA Cancer Drug Approvals	73
Figure 6 Growth rates of Cell Based Assays by Product Class	83
Figure 7 Global Market Share Chart	219
Figure 8 Global Market by User – Base vs. End Year	221
Figure 9 Global Market by User Base Year	222
Figure 10 Global Market by User End Year	223
Figure 11 User Share by Year	224
Figure 12 Global Market by Product Class – Base vs. End Year	226
Figure 13 Global Market by Product Class Base Year	227
Figure 14 Global Market by Product Class End Year	228
Figure 15 Product Class Share by Year	229
Figure 16 Pharma Growth	232
Figure 17 Research Growth	234
Figure 18 Industry/Cosmetic Growth	236
Figure 19 Instrument Growth	239
Figure 20 Reagent Growth	241

Figure 21 Services Growth243

Figure 22 Software Growth245

Figure 23 FDA Cancer Drug Approvals by Year247

Figure 24 Clinical Trials for Immunotherapy by Year.....248

Figure 25 Share of Pharma R&D by Country249